A chemogenomic screening identifies CK2 as a target for pro-senescence therapy in PTEN-deficient tumours.
Kalathur M, Toso A, Chen J, Revandkar A, Danzer-Baltzer C, Guccini I, Alajati A, Sarti M, Pinton S, Brambilla L, Di Mitri D, Carbone G, Garcia-Escudero R, Padova A, Magnoni L, Tarditi A, Maccari L, Malusa F, Kalathur RK, A Pinna L, Cozza G, Ruzzene M, Delaleu N, Catapano CV, Frew IJ, Alimonti A.
Kalathur M, et al. Among authors: alimonti a, a pinna l.
Nat Commun. 2015 Jun 18;6:7227. doi: 10.1038/ncomms8227.
Nat Commun. 2015.
PMID: 26085373
Free article.